Hodgkin lymphoma

Millennium: The Takeda Oncology Company and Seattle Genetics have commenced a Phase III trial designed to evaluate Adcetris for use as a frontline treatment regimen for advanced Hodgkin lymphoma (HL) in patients not previously treated with systemic chemotherapy or radiotherapy.

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) aimed at CD30, prevalent in both HL and systemic anaplastic large cell lymphoma, which has limited expression in healthy tissue.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Millennium chief medical officer Dr Karen Ferrante said the company is pleased to be starting the Phase III trial of Adcetris.

"This is a key step in our efforts to explore the potential of this targeted therapy as part of a frontline treatment regimen," Ferrante said.

"The trial is part of our ongoing development program to explore patient populations that may benefit from treatment with Adcetris in earlier lines of therapy and in other CD30-expressing malignancies."

See Also:

Around 1,040 eligible patients with stage III or IV classical HL will be enrolled in the randomised clinical trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Adcetris+AVD versus ABVD will be evaluated as frontline therapy for patients with previously untreated classical HL in the open-label trial.

The primary endpoint is the modified progression free survival (mPFS) per independent review facility assessment based on the revised response criteria for malignant lymphoma.

Overall survival (OS), complete remission (CR) and safety are the secondary end points of the multi-centre trial scheduled to be conducted in North America, Europe, Latin America and Asia.

Seattle Genetics chief medical officer Dr Thomas Reynolds said; "We believe through this novel Adcetris-containing regimen we have the potential to redefine the treatment of frontline HL."

Image: Micrograph of Hodgkin lymphoma, abbreviated HL. Lymph node FNA specimen. Photo: Courtesy of Nephron.